Katie Boda is an associate at Rakoczy Molino Mazzochi Siwik LLP.
Ms. Boda's practice focuses on intellectual property litigation, with emphasis on patent infringement suits arising under both the Hatch-Waxman Amendments to the Food, Drug and Cosmetic Act and Biologics Price Competition and Innovation Act (BPCIA).
Ms. Boda has experience representing clients in proceedings before U.S. District Courts. She routinely engages in a number of stages of complex, federal litigation, including pre-suit strategy development, fact and expert discovery, the pre-trial and trial. Additionally, Ms. Boda has experience with proceedings before the Patent Trial and Appeal Board and European Patent Office.
Ms. Boda has experience with respect to a wide range of pharmaceutical technologies, including with respect to biosimilar drug products, devices and manufacturing processes with respect to the same, pharmaceutical formulations, injectable dosage forms, inhalation dosage forms and devices, ophthalmic dosage forms, pharmaceutical dosing methods, and surgical methods.
Novo-Nordisk v. Shire (European Patent Office): Assisted European counsel with representation of Shire concerning a Factor VIII PEGylation patent. The European Patent Office upheld the grant of the European patent.
The Johns Hopkins University v. Alcon Laboratories, Inc. et al. (D. Del.): Represented Alcon in litigation concerning a surgical method patent.
Sun Pharma Global et al. v. Lupin Ltd et al. (D.N.J.) (bromfenac ophthalmic solution)
Boehringer Ingelheim Pharmaceuticals, Inc., et al. v. Lupin Atlantis Holdings SA, et al. (D.N.J.) (tiotropium bromide)
Prior to joining Rakoczy Molino Mazzochi Siwik LLP as an associate, Ms. Boda was a law clerk at Simmons Hanly Conroy LLC and Loren B. Siegel & Associates, LLC.